Sage Therapeutics Stock News

The 800+ hedge funds and famous money managers tracked by Insider Monkey have already compiled and submitted their 13F filings for the second quarter, which unveil their equity positions as of September

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sage Therapeutics, Inc. (NASDAQ: SAGE), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with

Investors are keenly aware that growth stocks have beaten value stocks five years in a row. So what am I going to recommend today?

The year 2021, was relatively mixed for biotech stocks with some posting significant gains while others pulled back dramatically. However, moving into 2022, we could see a significant rebound based on

Banque Cantonale Vaudoise boosted its holdings in Sage Therapeutics, Inc. (NASDAQ:SAGE) by 6.0% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 4,783 shares of the biopharmaceutical companys stock after acquiring an additional 272 shares during the quarter. Banque Cantonale Vaudoises holdings in [] The post Banque Cantonale Vaudoise Acquires 272 Shares of Sage Therapeutics, Inc. (NASDAQ:SAGE) appeared first on ETF Daily News .

Brokerages forecast that Sage Therapeutics, Inc. (NASDAQ:SAGE) will post $1.79 million in sales for the current quarter, Zacks reports. Eleven analysts have made estimates for Sage Therapeutics earnings, with the lowest sales estimate coming in at $1.40 million and the highest estimate coming in at $2.47 million. Sage Therapeutics posted sales of $1.69 million in []

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Today, Sage Therapeutics, Inc. (Nasdaq: SAGE), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating disorders of the brain, will host its third annual FutureCast: An R&D Portfolio Review to showcase the Companys research and development strategy, and clinical progress in its depression, neurology, and neuropsychiatry franchise programs. Sages expertise in brain circui

Robeco Institutional Asset Management B.V. lifted its position in shares of Sage Therapeutics, Inc. (NASDAQ:SAGE) by 786.5% during the third quarter, Holdings Channel reports. The firm owned 27,598 shares of the biopharmaceutical companys stock after acquiring an additional 24,485 shares during the period. Robeco Institutional Asset Management B.V.s holdings in Sage Therapeutics were worth $1,222,000 []

Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus EyePoint Announces Commercialization Agreement For Dexycu To Treat Post-Operative Inflammation EyePoin

(RTTNews) - Sage Therapeutics Inc. (SAGE) and Biogen Inc. (BIIB) said that new analyses from the landscape clinical development program of zuranolone in major depressive disorder or MDD were presented at the American College Of Neuropsychopharmacology Congress. Data from the SHORELINE and WATERFALL Studies in the LANDSCAPE clinical program